SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

SPARC shines on entering into licensing agreement with Bioprojet

19 Dec 2019 Evaluate

SPARC is currently trading at Rs. 167.50, up by 4.90 points or 3.01% from its previous closing of Rs. 162.60 on the BSE.

The scrip opened at Rs. 163.00 and has touched a high and low of Rs. 170.55 and Rs. 161.35 respectively. So far 127269 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 215.20 on 21-Dec-2018 and a 52 week low of Rs. 107.00 on 09-Jul-2019.

Last one week high and low of the scrip stood at Rs. 170.55 and Rs. 161.35 respectively. The current market cap of the company is Rs. 4399.78 crore.

The promoters holding in the company stood at 68.46%, while Institutions and Non-Institutions held 4.27% and 27.26% respectively.

Sun Pharma Advanced Research Company (SPARC) has entered into an agreement with Bioprojet SCR (Bioprojet) to exclusively acquire Bioprojet’s rights to the investigational medicinal product SCD-044. SPARC and Bioprojet co-owned all SCD-044 related IP, developed through a research collaboration targeting Sphingosine -1-Phosphate Receptors (S1PR) to treat various autoimmune disorders.

The acquisition includes full assignment of all patents and patent applications owned or controlled by Bioprojet related to SCD-044. Under the terms of the agreement, Bioprojet is eligible to receive milestones and royalties on net sales of SCD-044

SPARC is an international pharmaceutical company engaged in research and development of drugs and delivery systems.

Sun Pharma Adv. Res Share Price

147.90 -4.25 (-2.79%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Syngene Internation. 435.70
Indegene 486.80
CMS Info Systems 318.00
JITF Infralogistics 338.00
Sagility 42.95
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×